How India Exports Fulvestrant to the World

In the United States, the Food and Drug Administration (FDA) has approved multiple Abbreviated New Drug Applications (ANDAs) for fulvestrant, facilitating the availability of generic versions. For instance, Amneal Pharmaceuticals received approval for their ANDA 210044 on May 30, 2018, for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per syringe. The regulatory pathway for fulvestrant involves demonstrating bioequivalence to the reference listed drug, Faslodex, originally approved on April 25, 2002.

The presence of 84 active Indian exporters supplying fulvestrant to the U.S. market reflects a robust competitive landscape. This diversity ensures a steady supply chain, contributing to market stability and potentially influencing pricing dynamics.

Within the European Union, fulvestrant has been authorized for use in treating estrogen receptor-positive, locally advanced or metastatic breast cancer. The European Medicines Agency (EMA) granted marketing authorization for Fulvestrant Mylan on January 8, 2018, as a generic equivalent to Faslodex. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, ensuring consistent regulatory oversight.

Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions. This includes adherence to stringent quality control measures and regular inspections to maintain product integrity and patient safety.

Fulvestrant is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. This inclusion mandates adherence to international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, fulvestrant is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) oversees its pricing to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) prior to exporting pharmaceuticals, ensuring compliance with national regulations.

The primary patents for fulvestrant have expired, leading to increased generic competition. This has resulted in a more competitive market landscape, with multiple manufacturers offering generic versions, thereby enhancing accessibility and affordability for patients worldwide.

In June 2024, the EMA granted marketing authorization for Truqap (capivasertib) in combination with fulvestrant for the treatment of certain types of breast cancer, expanding therapeutic options for patients. (ema.europa.eu)

In November 2025, the EMA renewed the marketing authorization for Fulvestrant Mylan, affirming its continued safety and efficacy in the European market. (ema.europa.eu)

These developments reflect the dynamic nature of the pharmaceutical industry, with ongoing regulatory activities and market entries influencing the global availability and utilization of fulvestrant.

India's pharmaceutical industry heavily relies on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with approximately 70% sourced from China. This dependency exposes the supply chain to risks such as geopolitical tensions, trade restrictions, and production disruptions in China. For instance, regulatory overhauls in China have previously led to production halts, affecting global API availability.

To mitigate these risks, the Indian government launched the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to bolster domestic API and KSM manufacturing. By March 2025, this initiative resulted in import savings of ₹1,362 crore and established domestic production capacity for 25 critical APIs. However, fulvestrant's API and KSMs were not among the initial focus areas, indicating continued reliance on imports for its production.

The export market for fulvestrant from India is notably concentrated. The top five exporters—Intas Pharmaceuticals Limited (30.3% share), Jodas Expoim Private Limited (12.2%), Sun Pharmaceutical Industries Limited (11.4%), Dr. Reddy's Laboratories Limited (11.3%), and Alembic Pharmaceuticals Limited (9.9%)—collectively account for 75.2% of total exports. This high concentration poses a risk; disruptions at any of these key suppliers could significantly impact global supply.

While the PLI scheme has incentivized domestic production of certain APIs, its impact on fulvestrant's supply chain remains limited due to the program's initial focus on other critical drugs. As of March 2025, the scheme had led to substantial investments and import savings, but fulvestrant's API production has yet to benefit directly from these initiatives.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay shipments of pharmaceuticals, including fulvestrant, leading to supply shortages in destination markets. Additionally, ongoing U.S.-China trade tensions have heightened concerns over the stability of pharmaceutical supply chains, given the significant role both countries play in API production and export.

Regulatory agencies like the FDA and EMA have issued shortage alerts for various drugs in the past, underscoring the impact of supply chain vulnerabilities. While specific alerts for fulvestrant have not been prominent, the interconnectedness of global pharmaceutical supply chains means that disruptions in one area can have cascading effects on drug availability worldwide.

• Diversify API and KSM Sourcing: Encourage the development of alternative suppliers for fulvestrant's API and KSMs, both domestically and in other countries, to reduce reliance on a single source.

• Expand PLI Scheme Coverage: Advocate for the inclusion of fulvestrant's API and KSMs in the PLI scheme to promote domestic production and enhance supply chain resilience.

• Strengthen Supplier Relationships: Establish strategic partnerships with multiple suppliers to ensure a stable and diversified supply chain.

• Monitor Geopolitical Developments: Implement a robust monitoring system for geopolitical events that could impact shipping routes and API availability, allowing for proactive risk management.

• Enhance Inventory Management: Maintain adequate buffer stocks of fulvestrant and its raw materials to mitigate the impact of potential supply disruptions.

RISK_LEVEL: MEDIUM